Uncertainty and novel clinical trial designs in oncology – when should equipoise matter?
Sarah Heynemann, Wendy Lipworth, Sue-Anne McLachlan, Jennifer Philip, Tom John, Ian Kerridge · 2026
Read Uncertainty and novel clinical trial designs in oncology – when should equipoise matter? by Sarah Heynemann, Wendy Lipworth, Sue-Anne McLachlan, Jennifer Philip, Tom John, Ian Kerridge (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624340.txt.
Description
Heynemann and five co-authors ask when fairness between treatment arms should still govern cancer trials, in this two thousand twenty-six ethics article. Equipoise, the honest uncertainty about which arm is better, is the classic moral license for randomizing patients.
Modern oncology increasingly uses designs that break the classic mold: seamless trials that flow from one phase to the next, adaptive trials that shift as data arrives, and long-running platform trials. The authors argue these designs strain equipoise as a useful moral tool, because risk and uncertainty change shape mid-trial. Equipoise still anchors ordinary trials, they say, but new designs need additional ethical instruments to judge the risks participants take on.
Catalog record
| CREATOR | Sarah Heynemann, Wendy Lipworth, Sue-Anne McLachlan, Jennifer Philip, Tom John, Ian Kerridge |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |